The HDAC6 Knockout KYSE-150 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human esophageal squamous cell carcinoma (ESCC) cell line KYSE-150. This advanced cellular model features targeted disruption of the HDAC6 gene, resulting in a loss-of-function system for studying HDAC6-dependent processes. The polyclonal format preserves genetic heterogeneity akin to the parental line while eliminating functional HDAC6 expression, making it suitable for pooled functional assays and bulk analyses that do not require isogenic clonal derivation. Researchers can utilize this tool to interrogate the multifaceted roles of HDAC6 in oncogenic signaling, cytoskeletal regulation, and proteostasis without interference from endogenous gene activity.
The KYSE-150 cell line was established from a poorly differentiated esophageal squamous cell carcinoma and exhibits characteristics typical of malignant esophageal epithelial cells, including robust proliferative capacity and invasive potential. As an ESCC model, it retains key oncogenic drivers and signaling aberrations found in this aggressive carcinoma subtype. The cells grow adherently and are widely used in cancer biology research to study ESCC pathogenesis, therapeutic response, and metastatic mechanisms. Their genetic background provides a clinically relevant context for examining how HDAC6 loss influences disease-specific phenotypes such as migration, chemoresistance, and tumor growth.
HDAC6 functions primarily in the cytoplasm as a deacetylase targeting non-histone substrates, notably ??-tubulin, HSP90, and cortactin. By deacetylating ??-tubulin, HDAC6 modulates microtubule stability and dynamics, which are critical for cell motility and intracellular trafficking. Its action on HSP90 influences chaperone activity, affecting the stability of client proteins including EGFR, AKT, and HIF-1????upstream regulators of HDAC6 that also govern cell survival and stress responses. HDAC6 is itself regulated by signaling from EGFR and AKT, as well as by NF-??B and proteasome inhibition, which enhance its expression or activity. Downstream, HDAC6-mediated deacetylation of cortactin promotes actin remodeling and cell migration, while deacetylation of peroxiredoxin-1/2 impacts redox regulation. HDAC6 also interacts with the dynein motor complex, ubiquitinated proteins, and p97/VCP, facilitating the transport of misfolded protein aggregates to aggresomes for autophagic clearance. Thus, HDAC6 serves as a nexus linking signal transduction cascades??including the MAPK/ERK and NF-??B pathways??to cytoskeletal organization, protein quality control, and cell adhesion.
In the context of esophageal squamous cell carcinoma, HDAC6 is often implicated in enhanced invasive behavior and resistance to chemotherapy. By ablating HDAC6 in the KYSE-150 background, this model allows dissection of its contribution to ESCC aggressiveness. Researchers can investigate how loss of HDAC6 alters acetyl-??-tubulin levels, impacts microtubule dynamics, and suppresses migratory/invasive capacity in Transwell assays. Additionally, the model is valuable for studying aggresome-autophagy pathway dysregulation in cancer and evaluating the dependency of KYSE-150 cells on HDAC6 for survival under chemotherapeutic stress. The interplay between HDAC6 and key oncogenic kinases such as EGFR and AKT further positions this knockout system for exploring kinase-inhibitor combinations that may overcome resistance.
Typical applications include assessing HDAC6-dependent cell migration and invasion using scratch-wound or Transwell assays, interrogating aggresome formation via immunofluorescence, and validating HDAC6-selective inhibitors by measuring changes in acetyl-??-tubulin levels via Western blot. Co-immunoprecipitation experiments can elucidate altered interactions between HDAC6 substrates and their partners. Drug sensitivity assays with HDAC6 inhibitors or conventional chemotherapeutics, coupled with xenograft tumor growth studies, enable translational investigation of ESCC treatment strategies. This polyclonal knockout population thus provides a versatile platform for dissecting HDAC6 biology in an esophageal carcinoma background. For further inquiries, please contact Ascent Research.
